Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02407509 | Phase I Trial of VS-6766 Alone and in Combination With Everolimus(RAF/MEK) | completed | Phase 1 | 104 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT03032783 | A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity | completed | Phase 2 | 51 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER |
| 1 |
| Jan 29, 2026 |
| clinicaltrials |
| NCT03703167 | Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) | completed | Phase 1 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07036809 | Assessment of Antithrombin III, Protein C, Protein S and D-dimer in Acute Leukemia | completed | — | 90 | Muhamed Ahmed Abdelmoaty Muhamed AlhagrasyOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04116437 | Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment | completed | Phase 2 | 96 | BeiGeneINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04681105 | Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies | completed | Phase 1 | 13 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03159702 | Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation | completed | Phase 2 | 43 | Medical College of WisconsinOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT03740529 | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | completed | Phase 1 / Phase 2 | 803 | Loxo Oncology, Inc.INDUSTRY | 10 | Jan 27, 2026 | clinicaltrials |
| NCT04401774 | Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy | completed | Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT04914845 | KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia | completed | Phase 1 | 16 | University of Colorado, DenverOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05622682 | Vaccine Immune Recovery After Leukemia(VIRAL) | completed | — | 89 | Children's Hospital of PhiladelphiaOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT05665530 | A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies | completed | Phase 1 | 86 | Prelude TherapeuticsINDUSTRY | 10 | Jan 26, 2026 | clinicaltrials |
| NCT04139434 | Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML | completed | Phase 1 | 32 | Newave Pharmaceutical IncINDUSTRY | 2 | Jan 23, 2026 | clinicaltrials |
| NCT04593277 | Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study | completed | N/A | 549 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT02389517 | Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant | completed | Phase 2 | 42 | University of ChicagoOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT02862652 | Role of the Microparticles and of Tissue Factor in the Pro-thrombotic Phenotype and the Thromboembolic Complications During the Acute Lymphoblastic Leukemia in Children.(THROMBLEUKEMIA) | completed | N/A | 24 | CHU de ReimsOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05275543 | Robot Rehab: AAI With Robot During Inpatient Pediatric Rehab | completed | N/A | 25 | University of NebraskaOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07354191 | Outcome of Multiple Myeloma Associated With Autoimmune Hemolytic Anemia | completed | N/A | 66 | New Valley UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT00364286 | Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825) | completed | Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06068621 | Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 200 | Chinese PLA General HospitalOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06286332 | Music Therapy in Acute Leukemia Patients With Fatigue | completed | N/A | 60 | Chang Gung UniversityOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT02312102 | Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation | completed | Phase 1 | 22 | Massachusetts General HospitalOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT02969837 | Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma | completed | Phase 2 | 46 | University of ChicagoOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT00254423 | Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia | completed | Phase 2 | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT05063591 | Removing Transfusion Dependence as a Barrier to Hospice Enrollment(BRUOG-407) | completed | N/A | 18 | Adam OlszewskiOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT05466994 | A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Naïve Undergoing Surgery to Reduce Postoperative Opioid Use (GAMING-ON Study) | completed | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT02896582 | Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance(LyMa101) | completed | Phase 2 | 86 | The Lymphoma Academic Research OrganisationOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT02264613 | ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas | completed | Phase 1 / Phase 2 | 142 | Aileron Therapeutics, Inc.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT02441686 | Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 46 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT03210662 | Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT03414775 | Influences of High-fiber, Organic Whole-food Formula on the Gut Microbiome in Critically Ill Children | completed | N/A | 32 | University of PittsburghOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06558513 | To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors | completed | Phase 1 / Phase 2 | 120 | Evopoint Biosciences Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04134117 | Tisagenlecleucel In Primary CNS Lymphoma | completed | Phase 1 | 13 | Matthew J. Frigault, M.D.OTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04220684 | Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML | completed | Phase 1 | 19 | Sumithira VasuOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT03042689 | Study of Regorafenib in Patients With Advanced Myeloid Malignancies | completed | Phase 1 | 16 | Massachusetts General HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05625971 | Non-invasive MRD Assessment in Multiple Myeloma(NIRVANA) | completed | — | 36 | Rajshekhar Chakraborty, MDOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT01208766 | Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma(HO95) | completed | Phase 3 | 1,503 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 16 | Jan 6, 2026 | clinicaltrials |
| NCT03702725 | Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 14 | Alliance Foundation Trials, LLC.OTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05678998 | WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma | completed | Phase 1 | 25 | Werewolf Therapeutics, Inc.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT06031194 | Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma | completed | — | 20 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT06704243 | Peer Support Group for Adolescent and Young Adult (AYA) Allogeneic Stem Cell Transplant Recipients | completed | N/A | 13 | University Health Network, TorontoOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03904134 | Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)(BMT CTN 1702) | completed | N/A | 1,753 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Jan 5, 2026 | clinicaltrials |
| NCT02490891 | Study of the Angiogenesis by PET/CT in Patients With Lymphoma(RGDLymphome) | completed | Phase 2 | 21 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT02815137 | Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma(XPO1) | completed | N/A | 137 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT03594149 | Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients(AZABAC) | completed | Phase 3 | 60 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04174053 | Concordance Between 2 Means of Temperature Measure in Neutropenic Patients Hospitalized in Intensive Hematology Care Units(TEMPET) | completed | N/A | 30 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT05355987 | Impact of Paramedical Consultations in Oncological Supportive Care in Outpatients With Multiple Myeloma(SOSAM) | completed | N/A | 20 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT06141772 | Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapy(LYMPHO-CLEAR) | completed | N/A | 24 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT06395220 | Kinectics of Donor-specific Anti-HLA Antibody After HLA-incompatible Allogeneic Haematopoietic Stem Cell Transplantation | completed | — | 314 | Peking University People's HospitalOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04307134 | Besponsa Post Marketing Surveillance Study | completed | — | 108 | PfizerINDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 29, 2026source: clinicaltrials